ArticleMedical care2014
Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts.
Article in Medical care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Diagnostic Performance of Prostate Cancer Disease-Specific Phenotypes Identified Using Real-World Databases: A Systematic Review.Pharmacoepidemiology and drug safety · 2025Pooled it
- A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data.Journal of the National Cancer Institute · 2020Pooled it
- An Intervention to Increase Advance Care Planning Among Older Adults With Advanced Cancer: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Natural Language Processing to Identify Advance Care Planning Documentation in a Multisite Pragmatic Clinical Trial.Journal of pain and symptom management · 2022Trial
- Validation in Alberta of an administrative data algorithm to identify cancer recurrence.Current oncology (Toronto, Ont.) · 2020Trial
- Axillary Management in Clinically Node-Positive (cN1) Estrogen Receptor-Positive Breast Cancer.Cancers · 2026Article
- Sociodemographic disparities and hospice referral practice patterns among patients with recurrent cervical cancer.Gynecologic oncology reports · 2026Article
- Rule-Based Algorithm to Identify Recurrent Non-Hodgkin Lymphoma in Electronic Health Data.JCO clinical cancer informatics · 2026Article
- Estimate renal cell carcinoma recurrence rates using electronic health records.ESMO real world data and digital oncology · 2026Article
- Longitudinal Language-Model Reasoning Enables Automated Labeling of Lung Cancer Recurrence from Unstructured Clinical Records.Research square · 2026Article
- Using Electronic Health Records to Classify Cancer Site and Metastasis.Applied clinical informatics · 2025Article
- Patterns of recurrence among adults diagnosed with screen-detected lung cancer.Cancer epidemiology · 2025Article
- Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2- Metastatic Breast Cancer.Cancer medicine · 2025Observational
- Prognostic Significance of Recurrence and Timing of Recurrence on Survival Among Patients with Early-Stage Hepatocellular Carcinoma in U.S. Clinical Practice.Annals of surgical oncology · 2025Observational
- Associations Between Rehabilitation Utilization and Out-of-Pocket Costs Among Older Adults With Breast Cancer in the United States.Archives of physical medicine and rehabilitation · 2024Article
- Racial comparisons in treatment of rectal adenocarcinoma and survival in the military health system.JNCI cancer spectrum · 2024Article
- Accuracy of a Cancer Registry Versus Clinical Care Team Chart Abstraction in Identifying Cancer Recurrence.Mayo Clinic proceedings. Innovations, quality & outcomes · 2024Article
- Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors.British journal of cancer · 2024Article
- Evaluation of Algorithms Using Automated Health Plan Data to Identify Breast Cancer Recurrences.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Estimated incidence of disruptions to event-free survival from non-metastatic cancers in New South Wales, Australia - a population-wide epidemiological study of linked cancer registry and treatment data.Frontiers in oncology · 2024Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundA substantial proportion of cancer-related mortality is attributable to recurrent, not de novo metastatic disease, yet we know relatively little about these patients. To fill this gap, investigators often use administrative codes for secondary malignant neoplasm or chemotherapy to identify recurrent cases in population-based datasets. However, these algorithms have not been validated in large, contemporary, routine care cohorts.
objectiveTo evaluate the validity of secondary malignant neoplasm and chemotherapy codes as indicators of recurrence after definitive local therapy for stage I-III lung, colorectal, breast, and prostate cancer. RESEARCH DESIGN, SUBJECTS, AND MEASURES: We assessed the sensitivity, specificity, and positive predictive value (PPV) of these codes 14 and 60 months after diagnosis using 2 administrative datasets linked with gold-standard recurrence status information: CanCORS/Medicare (diagnoses 2003-2005) and HMO/Cancer Research Network (diagnoses 2000-2005).
resultsWe identified 929 CanCORS/Medicare patients and 5298 HMO/CRN patients. Sensitivity, specificity, and PPV ranged widely depending on which codes were included and the type of cancer. For patients with lung, colorectal, and breast cancer, the combination of secondary malignant neoplasm and chemotherapy codes was the most sensitive (75%-85%); no code-set was highly sensitive and highly specific. For prostate cancer, no code-set offered even moderate sensitivity (≤ 19%).
conclusionsSecondary malignant neoplasm and chemotherapy codes could not identify recurrent cancer without some risk of misclassification. Findings based on existing algorithms should be interpreted with caution. More work is needed to develop a valid algorithm that can be used to characterize outcomes and define patient cohorts for comparative effectiveness research studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.